Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Stapokibart (CM310) in CRSwNP
NCT05131464Phase 2Completed
- Sponsor
- Keymed Biosciences
- Start
- Nov 2021
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of stapokibart in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Keymed Biosciences. Started Nov 2021; status: completed.
02
Drugs
stapokibart
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT05131464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05131464.